You are here:
Imfinzi
monotherapy in endometrial cancer that is mismatch repair deficient (dMMR)
No estimate possible yet
Registered
Durvalumab
Oncology
Indication extension
Oncology other
AstraZeneca
PD-1 / PD-L1 inhibitor
Intracavernous
Intravenous drip
Intermural (MSZ)
https://www.ema.europa.eu/en/medicines/human/variation/imfinzi-0 DUO-E studie Durvalumab in combinatie met olaparib heeft CHMP opinie voor de pMMR groep
Decentralised
Normal trajectory
No
November 2023
September 2024
CHMP opinie juli 2024
There is currently nothing known about the expected patient volume.
There is currently nothing known about the expected cost.
There is currently nothing known about the possible total cost.
There is currently nothing known about off label use.
There is currently nothing known about indication extensions.
There is currently no futher information available.
Understanding of expected market entry of innovative medicines